Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Angiotensin-(1-7) vs BPC-157
An educational, source-based comparison of Angiotensin-(1-7) and BPC-157 — how each peptide works, what it's researched for, and what to know before going deeper.
Counter-regulatory peptide of the renin-angiotensin system.
A heptapeptide of the renin-angiotensin system that acts on Mas receptors. Research demonstrates counter-regulatory effects to angiotensin II, promoting vasodilation, anti-inflammatory signaling, and anti-fibrotic effects in cardiovascular and renal tissues.
- Pulmonary hypertension and fibrosis
- Heart failure with preserved ejection fraction
- Acute lung injury and ARDS
- Diabetic nephropathy
- • Investigational; not FDA-approved.
- • Interaction with ACE inhibitors and ARBs requires careful study design.
A pentadecapeptide (15 amino acids) derived from a protective protein found in human gastric juice. Research suggests it modulates the nitric oxide system, upregulates growth hormone receptors in injured tissue, and promotes angiogenesis (formation of new blood vessels) — mechanisms associated with accelerated tendon, ligament, muscle, and intestinal mucosa repair in preclinical models.
- Tendon-to-bone healing
- Ligament and muscle recovery
- Gastric ulcer protection
- Inflammatory bowel models
- Neuroprotection (rodent)
- • Human clinical trials are limited — most research is preclinical.
- • Not FDA-approved for human therapeutic use.
- • Quality, purity, and dosing of compounded peptides vary widely.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Two cited studies; independent replication needed.
3 cited studies; evidence base is growing.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Angiotensin-(1-7) | Angiotensin-(1-7) as a therapeutic in lung disease | American Journal of Respiratory and Critical Care Medicine | 2020 | Demonstrated protective effects in acute lung injury and pulmonary fibrosis models. |
| Angiotensin-(1-7) | Mas receptor activation in cardiovascular protection | Circulation Research | 2018 | Reviewed anti-inflammatory and anti-fibrotic mechanisms in cardiac tissue. |
| BPC-157 | Pentadecapeptide BPC 157 and the central nervous system | Neural Regeneration Research | 2022 | Review of neuroprotective and neurorepair signaling pathways observed in animal models. |
| BPC-157 | Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia/reperfusion in rats | Journal of Physiology - Paris | 2018 | Demonstrated mucosal protective effects and accelerated recovery from induced colitis. |
| BPC-157 | BPC 157 and tendon-to-bone healing | Journal of Orthopaedic Research | 2010 | Improved biomechanical recovery of transected Achilles tendons in rats. |
Side-effect & safety grid
- Investigational; not FDA-approved.
- Interaction with ACE inhibitors and ARBs requires careful study design.
- Human clinical trials are limited — most research is preclinical.
- Not FDA-approved for human therapeutic use.
- Quality, purity, and dosing of compounded peptides vary widely.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Angiotensin-(1-7) vs BPC-157 — Key differences
- Class: Angiotensin-(1-7) is classified as Cardiovascular · Anti-inflammatory, while BPC-157 is Tissue Repair · Gastrointestinal.
- Primary research focus: Angiotensin-(1-7) — pulmonary hypertension and fibrosis; BPC-157 — tendon-to-bone healing.
- Tag: Cardiovascular · Anti-inflammatory vs Recovery.
BPC-157 Research Protocol Table
Structured summary of dosing, routes, and durations as described in published research and FDA labels. Educational reference only — not dosing guidance.
| Context | Population | Route | Dose | Duration | Notes |
|---|---|---|---|---|---|
| Tendon and ligament recovery (preclinical) | Rodent models (rat, mouse) | Subcutaneous or intraperitoneal | 10 mcg/kg/day | 10–14 days in most cited studies | Animal data only; cited human-grade safety or efficacy evidence is not established. |
| GI mucosal recovery (preclinical) | Rodent models | Oral or intragastric in some studies; subcutaneous in others | 10–50 mcg/kg/day depending on study | 5–14 days | Frequently cited in gut-recovery literature; remains preclinical. |
| Anecdotal human research-use (non-clinical literature) | Adults, mixed; off-label | Subcutaneous | Commonly cited 250–500 mcg, 1–2× daily | 2–6 week cycles in user reports | Not validated by controlled human trials; FDA has flagged BPC-157 outside approved drug pathways. |
BPC-157 Research — Female vs Male Studies
How published BPC-157 research breaks down by sex, including which populations were studied and what trial data exist.
Female research
Female-specific clinical trial data for BPC-157 are essentially absent. Preclinical rodent studies have included female animals but do not isolate sex-based outcomes.
- Female rodents in tissue-recovery models
- • No published human RCTs stratified by sex.
- • Pregnancy, lactation, and hormonal-cycle effects have not been characterized.
Male research
Male-specific clinical data are similarly limited. Most cited animal studies use male rodents for tendon, ligament, and GI models.
- Male rodents in tendon/ligament/GI repair models
- • No published human RCTs in men.
- • Anecdotal human use reports skew male but do not constitute clinical evidence.
BPC-157 — Frequently Asked Questions
Is BPC-157 FDA-approved?+
No. BPC-157 is not FDA-approved for any indication. It has appeared on the FDA's bulk-substance review lists as not eligible for traditional compounding under current evidence.
What does research suggest BPC-157 is studied for?+
Most cited BPC-157 research involves rodent models of tendon, ligament, and gastrointestinal mucosal recovery. Human controlled trial data remain very limited.
Are BPC-157 protocols the same for men and women?+
Published literature does not separate BPC-157 dosing by sex. There are no controlled human trials establishing sex-specific protocols.